Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American menopause society

Menopause

Volumn 17, Issue 2, 2010, Pages 242-255

[No Author Info available]

Author keywords

Bioidentical hormones; Breast cancer; Cardiovascular disease; Cognitive decline; Coronary heart disease; Dementia; Depression; Diabetes mellitus; Endometrial cancer; Estrogen; Estrogen progestogen therapy; Estrogen therapy; Hormone replacement therapy

Indexed keywords

CONJUGATED ESTROGEN; DROSPIRENONE; ESTRADIOL; ESTRIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE;

ADD ON THERAPY; ADULT; BLOOD PRESSURE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; DYSPAREUNIA; ENDOMETRIUM CANCER; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE ORGANIZATION; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MASTALGIA; MEDICAL EXPERT; MEDICAL SOCIETY; MENOPAUSE; MENOPAUSE RELATED DISORDER; NIGHT SWEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; OVARY CANCER; PHYSICIAN; POPULATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; STRESS INCONTINENCE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINAL INJURY; VAGINITIS; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTERONE; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77949345161     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181d0f6b9     Document Type: Review

References (74)

1. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.
2. Bachmann GA, Schaefers M, Uddin A, Utian WH. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause 2009;16:877-882.
3. Dedeoglu EN, Erenus M, Yoruk P. Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertil Steril 2009;91:425-431.
4. Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008;168:840-846.
5. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab 2008;93:4567-4575.
6. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 2009;12:106-113.
7. Thurston RC, Sowers MR, Chang Y, et al. Adiposity and reporting of va-somotor symptoms among midlife women: the Study of Women-s Health Across the Nation. Am J Epidemiol 2008;167:78-85.
8. Islam S, Liu Q, Chines A, Helzner E. Trend in incidence of osteoporosis-related fractures among 40-to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009;16:77-83.
9. The North American Menopause Society. The management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54.
10. Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. Metabolism 2009;58:1-7.
11. Allison MA, Manson JE, Langer RD, et al. for the Women-s Health Initiative and Women-s Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women-s Health Initiative coronary artery calcium study. Menopause 2008;15:639-647
12. Allison MA, Manson JE. The complex interplay of vasomotor symptoms, hormone therapy, and cardiovascular risk. Menopause 2009;16:619-620.
13. Bray PF, Larson JC, Lacroix AZ, et al, for the Women-s Health Initiative Investigators. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101:1599-1605.
14. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231.
15. Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol-micronized progesterone or low-dose estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril 2009;92:605-612.
16. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart Trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922-930.
17. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.
18. Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009;16:639-643.
19. Liu S, Tinker L, Song Y, et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch Intern Med 2007;167:1676-1685.
20. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-2668.
21. Pentti K, Tuppurainen MT, Honkanen R, et al. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 2009;160:979-983.
22. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women-s Health Initiative trials of hormone therapy. Arch Intern Med 2008;168:2245-2253.
23. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336-340.
24. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women-s Health Across the Nation Heart Study. Circulation 2008;118: 1234-1240.
25. Tinker LF, Bonds DE, Margolis KL, et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women-s Health Initiative randomized controlled Dietary Modification Trial. Arch Int Med 2008;168:1500-1511.
26. American Cancer Society. Cancer Facts & Figures 2009. Available at: http:// www.cancer.org/docroot/STT/stt-0.asp. Accessed November 29, 2009.
27. Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr Oncol 2009;16:21-25.
28. Beral V, for the Million Women Study Collaborators, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551.
29. Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 2009;115:936-945.
30. Chlebowski RT, Kuller LH, Prentice RL, et al, for the WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-587.
31. Chlebowski RT, Schwartz AG, Wakelee H, et al, for the Women-s Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women-s Health Initiative trial): a post-hoc analysis of a randomized controlled trial. Lancet 2009;274:1243-1251.
32. Crandall CJ, Aragaki AK, Chlebowski RT, et al. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med 2009;169:1684-1691.
33. Eisen A, Lubinski J, Gronwald J, et al, for the Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-1367.
34. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. Fournier A, Boutron-Ruault MC, Clavel-Chapelon F. Breast cancer and hormonal therapy in postmenopausal women. N Engl J Med 2009;360: 2366.
35. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007;13:453-463.
36. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999;86:1013-1018.
37. Holmberg L, Iversen OE, Rudenstam CM, et al. for the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-482.
38. Huang B, Carloss H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer 2009;15:4167-4175.
39. Johnson JR, Lacey JV Jr, Lazovich D, et al. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 196-203.
40. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009;14:1197-1204.
41. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmeno-pausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113:65-73.
42. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
43. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Available at: http://seer.cancer.gov/statfacts/html/breast.html. Accessed November 29, 2009.
44. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169: 41-46.
45. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women-s Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407-1415.
46. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus proges-tin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-1216.
47. Ritenbaugh C, Stanford JL, Wu L, et al. for the Women-s Health Initiative Investigators. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women-s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008;17:2609-2618.
48. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007; 25:3437-3439.
49. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008;100:563-571.
50. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2548-2556.
51. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113-123.
52. Stefanick ML, Anderson GL, Margolis KL, et al. for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295: 1647-1657.
53. Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008;108:641-651.
54. Asthana S, Brinton RD, Henderson VW, et al. for the Frontiers Proposal for Estrogen and Cognitive Aging Work Groups. Frontiers proposal. National Institute on Aging Bbench to bedside: estrogen as a case study.[Age (Dordr) 2009;31:199-210.
55. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology 2009;72:125-134.
56. Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 2009;72:1850-1857.
57. Henderson VW. Estrogens, episodic memory, and Alzheimer's disease: a critical update. Semin Reprod Med 2009;27:283-293.
58. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008:CD003122.
59. Maki PM, Sundermann E. Hormone therapy and cognitive function. Hum Reprod Update 2009;15:667-681.
60. Persad CC, Zubieta JK, Love T, Wang H, Tkaczyk A, Smith YR. Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy. Fertil Steril 2009;92:197-204.
61. Resnick SM, Espeland MA, An Y, et al. for the Women's Health Initiative Study of Cognitive Aging Investigators. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab 2009;94:4152-4161.
62. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology 2009;72:135-142.
63. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
64. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinson-ism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-209.
65. Rocca WA, Grossardt BR, Geda YE, et al. Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy. Menopause 2008;15: 1050-1059.
66. Rocca WA, Shuster LT, Grossardt BR, et al. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) 2009;5:39-48.
67. Banks E, Canfell K. Invited Commentary: Hormone therapy risks and benefitsVThe Women-s Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009;170:24-28.
68. Barbaglia G, Macia F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women-s Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-1064.
69. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009:CD004143.
70. Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. Menopause 2009;16: 1213-1217.
71. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
72. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42-52.
73. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016-1022.
74. Rosenthal MS. The Wiley Protocol: an analysis of ethical issues. Menopause 2008;15:1014-1022.